Samsung Biologics fully acquires Samsung Bioepis for $2.3B
Samsung Biologics has full ownership over Samsung Bioepis after purchasing Biogen’s stake
Samsung Biologics has completed the full acquisition of Samsung Bioepis after buying Biogen’s stake in the joint venture for $2.3 billion. The company completed the first payment of $1 billion pursuant to the terms of the acquisition agreement this week and will pay the remaining $1.3 billion in instalments over two years.
Samsung Bioepis is a biopharmaceutical company dedicated to developing and manufacturing biosimilar medicines.
Samsung Biologics CEO John Rim said the announcement ‘marks a significant milestone’ for the company in its ‘continued venture into the biosimilar business and accelerating biosimilar growth’.
He continued: ‘By leveraging our extensive experience as a leading CDMO, we will further contribute to saving lives of the patients and address a wide array of diseases.’
The company says its acquisition will give Samsung Bioepis improved autonomy and agility in business operations, accelerating sales growth as well as biosimilar development capabilities and future performance in novel drug development.
The purchase was funded by a portion of paid-in capital increase of KRW 3 trillion (approximately $2.5 billion) raised by issuing new shares, the proceeds of which will be used to fund the company’s strategic growth plans.
Samsung Biologics recently announced that its Plant 4 will be partially operational by October, 2022 and fully operational by mid-2023, at which time the company is expected to hold the world’s largest biomanufacturing capacity. It is also in the process of securing land for its new Bio Campus II, which will be 30% larger than the current site to enable future growth.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...